LAUSR

While glucagon‐like peptide‐1 (GLP‐1) was reported to have a positive impact on Parkinson disease, it is extremely short half‐life greatly hindered its clinical use. In this study, the mouse strain MG1363‐pMG36e‐GLP‐1 was engineered to continuously express GLP‐1 to treat Parkinson disease in a 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine (MPTP)‐treated Parkinson disease model. In our study, oral supplementation with MG1363‐pMG36e‐GLP‐1 significantly (p < 0.05) reduced MPTP‐induced locomotor impairments, increased tyrosine hydroxylase‐positive neurons, suppressed microglia and astrocyte activation, and down‐regulated expression of several inflammation‐related molecules. In addition, MG1363‐pMG36e‐GLP‐1 significantly (p < 0.01) reduced intestinal pathogen Enterobacteriaceae and markedly enhanced the number of probiotic Lactobacillus and Akkermansia. These data suggest that MG1363‐pMG36e‐GLP‐1 could be a novel therapeutic means for Parkinson disease.